Want to see CRNX full AI Analyst Report?
CRNX Stock Chart & Stats
$84.86
<$0.01(0.01%)
At close: 4:00 PM EDT
$84.86
<$0.01(0.01%)
Day’s Range― - ―
52-Week Range$31.00 - $85.01
Previous CloseN/A
Volume9.77K
Average Volume (3M)2.68M
Market Cap
$9.01B
Enterprise Value$2.79K
Total Cash (Recent Filing)$1.21B
Total Debt (Recent Filing)$47.19M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Nov 17, 2026EPS Estimate
-1.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.05
Shares Outstanding106,065,230
10 Day Avg. Volume3,015,448
30 Day Avg. Volume2,682,785
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)4.41
Price to Sales (P/S)568.91
P/FCF Ratio-11.41
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$85.56Price Target Upside0.82% Upside
Rating ConsensusHold
Number of Analyst Covering11
EPS Forecast (FY)-4.49
Revenue Forecast (FY)$79.38M
Bulls Say, Bears Say
Bulls Say
Early Commercial TractionInitial product demand provides a commercial foundation beyond clinical development. Revenue and enrollment growth can compound as prescriber adoption expands, supporting a durable transition toward a marketed-product business.
Pipeline Depth And Clinical ProgressMultiple endocrine-focused programs diversify the company beyond one product and preserve substantial development optionality. Active pivotal studies and supportive efficacy data could expand the addressable market over the next several years.
Strong Balance Sheet And Funding RunwayA large liquidity position and low leverage give Crinetics flexibility to fund commercialization and pivotal trials without immediate balance-sheet strain. The extended runway reduces dependence on near-term capital markets while programs mature.
Bears Say
Severe Losses And Cash BurnThe company remains structurally unprofitable and consumes substantial cash relative to current revenue. Unless commercialization scales materially or spending moderates, persistent losses could erode the equity base and sustain a high funding requirement.
High Operating InvestmentLarge research, development and commercial investments are necessary for pipeline advancement but create limited operating leverage today. If launches or trials progress more slowly than planned, the elevated cost base could prolong losses and cash consumption.
Commercial And Development Execution ConstraintsUnresolved reimbursement, treatment-center capacity and clinical-timing issues can delay revenue conversion and milestone visibility. These constraints may slow adoption and make the pipeline’s contribution to sustainable growth less predictable.
Crinetics Pharmaceuticals News
CRNX FAQ
What was Crinetics Pharmaceuticals’s price range in the past 12 months?
Crinetics Pharmaceuticals lowest stock price was $31.00 and its highest was $85.01 in the past 12 months.
What is Crinetics Pharmaceuticals’s market cap?
Crinetics Pharmaceuticals’s market cap is $9.01B.
When is Crinetics Pharmaceuticals’s upcoming earnings report date?
Crinetics Pharmaceuticals’s upcoming earnings report date is Nov 17, 2026 which is in 75 days.
How were Crinetics Pharmaceuticals’s earnings last quarter?
Crinetics Pharmaceuticals released its earnings results on Aug 03, 2026. The company reported -$1.14 earnings per share for the quarter, beating the consensus estimate of -$1.179 by $0.039.
Is Crinetics Pharmaceuticals overvalued?
According to Wall Street analysts Crinetics Pharmaceuticals’s price is currently Undervalued.
Does Crinetics Pharmaceuticals pay dividends?
Crinetics Pharmaceuticals does not currently pay dividends.
What is Crinetics Pharmaceuticals’s EPS estimate?
Crinetics Pharmaceuticals’s EPS estimate is -1.16.
How many shares outstanding does Crinetics Pharmaceuticals have?
Crinetics Pharmaceuticals has 106,065,230 shares outstanding.
What happened to Crinetics Pharmaceuticals’s price movement after its last earnings report?
Crinetics Pharmaceuticals reported an EPS of -$1.14 in its last earnings report, beating expectations of -$1.179. Following the earnings report the stock price went up 0.119%.
Which hedge fund is a major shareholder of Crinetics Pharmaceuticals?
Currently, no hedge funds are holding shares in CRNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crinetics Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$85.56 (0.82% Upside)
$85.56 (0.82% Upside)
Blogger Sentiment
Neutral
CRNX Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 697.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.9%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
CRNX Company Deck
CRNX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong early commercial launch for Palsonify with meaningful patient additions, encouraging reimbursement progress (≈70% reimbursed, >60% coverage), expanding prescriber footprint and robust pipeline advancement, all supported by a strong balance sheet. Offsetting these positives are elevated and rising R&D and operating expenses, limited disclosure of certain commercial conversion metrics, a remaining reimbursement gap (~30% of patients), appointment‑driven adoption constraints, and no firm timelines provided for several key pivotal readouts or international revenue. On balance, the positives around launch momentum, payer traction, prescriber growth and cash runway outweigh the operational and disclosure limitations.View all CRNX earnings summariesCRNX Stock 12 Month Forecast
Average Price Target
$85.56
▲(0.82% Upside)
Technical Analysis
Ownership Overview
0.16% Insiders
40.86% Mutual Funds
39.22% Other Institutional Investors
3.56% Public Companies and
Individual Investors